Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck - Related Studies

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

This study has been completed.

Study NCT00077428. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Head and Neck Cancer

2	Additional conditions recognized in this trial
		Carcinoma
		Carcinoma, Adenoid Cystic
		Head and Neck Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial

4	Interventions listed in this trial
		bortezomib
		doxorubicin hydrochloride

5	Additional drug interventions recognized in this trial
		Doxorubicin

6	More general drug interventions related to this trial
		Antibiotics, Antineoplastic
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protease Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Eastern Cooperative Oncology Group
		National Cancer Institute (NCI)
		Southwest Oncology Group